PTC Therapeutics prices $500M 0% convertible notes due 2031 to refinance 2026 notes

PTC THERAPEUTICS, INC.

Priced $500M aggregate principal of 0% Convertible Senior Notes due 2031; initial purchasers have option for additional $50M.
Conversion price set at $107.48 per share, a 40% premium over June 15 closing price of $76.77.
Approximately $328.8M of net proceeds will be used to repurchase $222M of outstanding 1.5% convertible notes due 2026.
Closing expected on June 18, 2026; notes are senior unsecured obligations and mature June 15, 2031.
Remaining net proceeds will be used for general corporate purposes, including potential additional repurchases of 2026 notes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.